Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Mounjaro’s typical maintenance dosage is 5 mg per week. If needed, your doctor might increase your dose in increments of 2.5 mg every 4 weeks, up to a maximum of 15 mg per week. You’ll ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Through the third quarter of 2024, Lilly generated total revenue of $31.5 billion -- an increase of 27% year over year. Roughly $15 billion of this total stems from just three drugs -- Mounjaro ...

This will be done after another period of 4 weeks, and in increments of 2.5 mg, if needed. For Mounjaro, 15 mg per week is the maximum dosage. For details about Mounjaro’s dosage, you can refer ...

Two of the most recommended meds nowadays that may aid in reducing weight are Mounjaro and Ozempic ... dosage as much as 2.5 mg every 4 weeks up to a maximum dose of 15 mg once a week.

While much attention focuses on Lilly's incretin franchise, Mounjaro and Zepbound ... the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...